Tolterodine Drug Use Investigation.(Post Marketing Commitment Plan)
Status:
Completed
Trial end date:
2011-03-01
Target enrollment:
Participant gender:
Summary
The objective of this surveillance is to collect information about 1) adverse drug reaction
not expected from the Package Insert (unknown adverse drug reaction), 2) the incidence of
adverse drug reactions in this surveillance, and 3) factors considered to affect the safety
and/or efficacy of this drug.
Details
Lead Sponsor:
Pfizer Pfizer's Upjohn has merged with Mylan to form Viatris Inc.